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ABSTRACT
Background: Parenteral nutrition (PN) is the main treatment for
intestinal failure.
Objective: We aimed to review the indications for home parenteral
nutrition (HPN) in children and describe the outcome over a 14-y
period from a single center.
Design: We conducted a retrospective study that included all chil-
dren who were referred to our institution and discharged while re-
ceiving HPN between 1 January 2000 and 31 December 2013. The
indications for HPN were divided into primary digestive diseases
(PDDs) and primary nondigestive diseases (PNDDs). We compared
our results to a previous study that was performed in our unit from
1980 to 2000 and included 302 patients.
Results: A total of 251 patients were included: 217 (86%) had
a PDD. The mean 6 SD age at HPN onset was 0.7 6 0.3 y, with
a mean duration of 1.9 6 0.4 y. The indications for HPN were short
bowel syndrome (SBS) (59%), PNDD (14%), congenital enteropa-
thies (10%), chronic intestinal pseudo-obstruction syndromes (9%),
inflammatory bowel diseases (5%), and other digestive diseases
(3%). By 31 December 2013, 52% of children were weaned off
of HPN, 9% of the PDD subgroup had intestinal transplantation, and
10% died mostly because of immune deficiency. The major com-
plications of HPN were catheter-related bloodstream infections
(CRBSIs) (1.7/1000 d of PN) and intestinal failure-associated liver
disease (IFALD) (51 children; 20% of cohort). An increased rate of
CRBSIs was observed compared with our previous study, but we
saw a decreasing trend since 2012. No noteworthy deceleration of
growth was observed in SBS children 6 mo after weaning off HPN.
Conclusions: SBS was the major indication for HPN in our cohort.
IFALD and CRBSIs were potentially life-threatening problems.
Nevertheless, complication rates were low, and deaths resulted
mostly from the underlying disease. Am J Clin Nutr
2016;103:1327–36.
Keywords: home parenteral nutrition, children, outcome,
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INTRODUCTION
Intestinal failure (IF)7 is defined as a critical reduction of
functional gut mass below the minimum needed for adequate
growth in children and weight maintenance in adults (1–5). This
condition requires parenteral nutrition (PN) as long as the in-
testinal function is insufficient. In developed countries, primary
digestive diseases (PDDs) responsible for IF fall into 3 groups:
short bowel syndrome (SBS) [including long-segment Hirschsprung
disease], congenital enteropathies (CEs) caused by genetic
defects in the enterocytes, and chronic intestinal pseudo-
obstruction syndrome (CIPOS) (1).
Whatever the cause of IF, long-term PN is the mainstay of
therapy (2, 5). Children with primary nondigestive diseases
(PNDDs) such as immune deficiencies (IDs) can also benefit
from PN (6). Home PN (HPN) allows children to grow in their
familial environment (2, 4, 7, 8). In France in 2014, the number
of patients aged ,18 y and receiving HPN was 262 for 65
million inhabitants, with an incidence of w50 new cases/y
(3, 5). Our institution has the largest pediatric HPN program in
Europe (6).
The survival of children on long-term PN increased dramat-
ically during the past 3 decades (1, 3, 5, 6). Nevertheless,
complications such as catheter-related bloodstream infections
(CRBSIs), intestinal failure–associated liver disease (IFALD),
and loss of venous access can challenge the prognosis (1, 5, 9).
Liver failure is the major life-threatening complication and is an
indication of combined liver and small bowel transplantation
(L-SBTx) (10, 11).
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A multidisciplinary team, appropriate handling of central
venous catheters (CVCs), and tailored HPN are crucial de-
terminants of prognosis (1, 10). Intestinal transplantation (ITx)
is indicated only in patients with irreversible IF who develop
life-threatening complications (2). An early referral to an IF
expert center is mandatory for a case-by-case treatment strategy
(12, 13).
The aim of this study was to review the indications and
outcomes of pediatric HPN over a 14-y period in a large cohort
managed in a single certified French center.
METHODS
Criteria for inclusion
According to the French Regional Health Agency, our hospital
is the single certified HPN “expert” center for children. Six other
hospitals are certified for managing HPN in pediatric patients in
France. All patients requiring HPN must be referred to one of
these centers to be supported by social security. Children were
eligible for HPN when they received PN for .3 mo while in
stable condition and with the prospect of long-term PN de-
pendency.
Patients’ referral and geographic origin
All children discharged while receiving HPN between 1
January 2000 and 31 December 2013 were included. They were
referred by our institution, hospitals in the Ile-de-France (IDF)
area (Paris and surrounding suburbs), and hospitals outside IDF.
For hospitals outside IDF, the follow-up included a routine
evaluation in our hospital’s outpatient clinics, whereas emergent
situations were mostly managed by the local hospital of origin.
Definition of PDD and PNDD subgroups
PDDs were defined as IF caused by SBS, CE, CIPOS, and
inflammatory bowel disease (IBD). The SBS included intestinal
atresia, midgut volvulus, necrotizing enterocolitis, gastroschisis,
long-segment Hirschsprung disease, and other causes of PDD.
The remnant bowel was measured at the time of surgery along the
antimesenteric border from the Treitz ligament. Congenital en-
teropathies included microvillus inclusion disease, congenital
tufting enteropathy, trichohepatoenteric syndrome, and others.
PNDD included patients with a variety of disorders that impaired
digestive functions and intestinal autonomy (e.g., ID and met-
abolic disorders).
Vascular access and handling
All children had a CVC Broviac-type or arteriovenous fistula.
They were all inserted under general anesthesia in the superior
vena cava after a vascular ultrasound. In 2007, we started using
mild soap and hydroalcoholic solutions for handwashing.We also
switched to mechanical valve needleless connectors on the CVC
to avoid needle stick injuries, better visualize the internal
structure, and reduce the use of prophylactic thrombolytic agents.
After weaning off PN, the CVC was kept for 3–6 mo.
PN intake
The PN formula was prepared by Fasonut-Baxter and delivered
weekly to the children’s homes with the use of a specialized
transportation along with the infusion materials. It was cus-
tomized for each child with the use of a compartment bag for
glucose, amino acids, electrolytes, minerals, vitamins, and trace
elements and another for intravenous lipid emulsion. The amino
acids were Vinte`ne (Baxter) for children aged .10 y and Va-
minolact (Fresenius Kabi) or Prime`ne (Baxter) for children
aged #10 y. The nonprotein energy intake (NPEI) included the
energy provided by glucose and lipids in the PN. The optimal
TABLE 1
Indications for HPN1
Patients, n (%)
PDDs
SBS 148 (59)
Atresia 16 (6)
Midgut volvulus 42 (17)
NEC 31 (12)
Gastroschisis 30 (12)
LSHD 25 (10)
Other 4 (2)
CIPOS 23 (9)
Congenital enteropathies 25 (10)
MVID 9 (4)
CTE 7 (3)
THE 4 (2)
Other 5 (2)
IBD 13 (5)
Crohn disease 9 (4)
Colitis 4 (2)
Other 8 (3)
PNDDs
ID 25 (10)
Other 9 (4)
Metabolic disease 3 (1)
Cancer 2 (1)
Cystic fibrosis 2 (1)
Inoperable cardiomyopathy 2 (1)
1CIPOS, chronic intestinal pseudo-obstruction syndrome; CTE, congen-
ital tufting enteropathy; HPN, home parenteral nutrition; IBD, inflammatory
bowel disease; ID, immune deficiency; LSHD, long-segment Hirschsprung
disease; MVID, microvillus inclusion disease; NEC, necrotizing enterocoli-
tis; PDD, primary digestive disease; PNDD, primary nondigestive disease;
SBS, short bowel syndrome; THE, trichohepatoenteric syndrome.
FIGURE 1 Geographic origin of children starting HPN per year. Paris
and the surrounding suburbs (IDF) are shown in black. Areas outside of IDF
are shown in gray. HPN, home parenteral nutrition; IDF, Ile-de-France.
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ratio of NPEI per gram of nitrogen was 150–250:1 according to
age. Intravenous lipid emulsions were Clinoleic (Baxter) from
2000 to 2008 and then soybean oil, medium-chain triglycerides,
olive oil, and fish oil (Fresenius Kabi) from 2009. They repre-
sented 10–30% of the NPEI. PN was supplemented with elec-
trolytes, trace elements (Aguettant), and vitamins (Cernevit
Clintec Parenteral).
Enteral feeding
Patients requiring long-term PN for SBS were preferentially
orally fed to promote intestinal adaptation. Enteral tube feeding
(ETF) was used in 2 situations: in children with eating disorders
and for some children during the process of PN weaning by
replacing 1 night of PN infusion by ETF. The latter was ad-
ministered by a nasogastric tube or gastrostomy and with the use
of extensively hydrolyzed formulas. Congenital enteropathies
and CIPOS did not receive ETF.
PN training, discharge, and follow-up
The parents were trained in our institution by specialist nurses
for 2–3 wk. A home nursing service supported by social security
can be available daily for parents who cannot or do not wish to
provide care. Once discharged from the hospital, parents were
accompanied home by an HPN nurse and could call our division
24 h. Whenever a child in our HPN program was admitted to
another hospital, we were contacted and updated regularly about
his or her health condition, and a medical report was sent to us at
discharge. Follow-up was performed in a specific multidisci-
plinary outpatient clinic by a gastroenterologist, pharmacist,
dietitian, and HPN nurse 4 times/y or more if needed. The
composition and volume of the PN solution were adapted to the
child’s requirements and growth. Assessment included a blood
exam [cell blood count, electrolytes, calcium, phosphorus,
magnesium, iron, and liver function tests and, once a year, vi-
tamins A, E, and 25-hydroxyvitamin D], insulin-like growth
factor-1, parathyroid hormone, trace elements, and lipid profiles.
The drawing was done from either the CVC or the peripheral
vein according to age and/or easiness for the child. A urinary
analysis was performed for electrolytes, calcium, and phos-
phorus. The number of HPN weekly infusions and calories were
slowly decreased and adjusted to the oral feeding of the child,
taking into account the remaining bowel length in SBS children.
The resting energy expenditure (REE) was calculated with the
use of Schofield formulas (14). We routinely used the ratio NPEI
from PN to REE to reflect the level of PN dependency rather
than the isolated enteral calories, which might be impeded by
intestinal reduced absorption. Herein we considered the last
values available in our files at the end of the study. The PN was
stopped when the calories were decreased to ,20% of REE.
Data collection and analysis
The collection of data included demographics, indication for
HPN, length of remnant small bowel, presence of ileocecal valve
(ICV), liver function tests (LFTs), liver biopsy if available,
complications related to CVC (infection, thrombosis, tearing),
CVC replacements, date and cause of HPN discontinuation, and
growth of children with SBS. The data were collected on 31
December 2013 or on the date of HPN discontinuation.
Definition of outcome and prognosis factors
Outcome was defined as the status of the patient at the end of
the study period: PN weaning, ITx, or death. These data were
studied according to the indication for HPN and the occurrence of
IFALD and CRBSI. The indications for ITx were end-stage liver
disease, extensive vascular thrombosis, repeated life-threatening
CRBSI and dehydration episodes. A multidisciplinary group of
gastroenterologists, hepatologists, surgeons, and anesthesiolo-
gists decided upon ITx (either isolated ITx or L-SBTx) after
collective discussions. The child was registered on the French
Biomedicine Agency list as extremely urgent, critical, or stable
according to his or her health condition. The reported mortality
rates corresponded to patients who died while still receiving
HPN.
Catheter-related complications
CRBSI was defined as a fever of .388C with $2 blood
samples growing for the same pathogen (1 sample from the
CVC and the other from the peripheral vein or 2 samples from
the CVC) with no other infection site. Children were divided
into 2 subcategories: history of at least 1 CRBSI (.1 CRBSI) or
no history of CRBSI. The diagnosis of tunnelitis was clinical
with local signs of infection along the CVC subcutaneous
pathway. The CVC was removed only in case of fungal in-
fection, tunnelitis, secondary infection (endocarditis, osteitis, or
arthritis), resistance to antibiotics, or failure of repairing a rup-
tured CVC. Since October 2011, we used Taurolidine-citrate
locks (TauroLock) for children who had $2 CRBSIs over
a 12-mo period. When parents were unable to infuse through
CVC, a catheter thrombosis was suspected. The child was ur-
gently hospitalized, and an Actosolv lock (Urokinase) was ad-
ministrated according to the unit protocol. A vascular ultrasound
was also performed. A blood coagulation workup was done
when a child had .2 episodes of thrombosis.
Assessment of liver disease
The definition of IFALD was based on an abnormal LFT
(transaminases, bilirubin, or g-glutamyl-transpeptidase) .1.5
times the upper limit of normal. A liver biopsy was performed
when abnormal LFTs persisted for .6 mo and the screening for
hepatotropic virus was negative. The METAVIR classification
was used to assess the severity of liver disease (17).
TABLE 2
Age distribution at HPN onset1
,1 y $1–5 y .5–10 y .10–15 y .15 y
SBS 108 26 6 5 3
CE 24 1 0 0 0
CIPOS 3 6 7 4 3
IBD 3 1 1 6 2
Other PDDs 2 2 1 2 1
ID 3 16 3 2 1
Other PNDDs 1 3 1 3 1
1CE, congenital enteropathy; CIPOS, chronic intestinal pseudo-obstruction
syndrome; HPN, home parenteral nutrition; IBD, inflammatory bowel disease;
ID, immune deficiency; PDD, primary digestive disease; PNDD, primary
nondigestive disease; SBS, short bowel syndrome.
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Growth of children with SBS
We studied the growth of children with SBS because they did
not receive corticosteroids, unlike other subgroups. The effect on
growth of iatrogenic elements other than HPN was absent or
minimal. Children were weighed with the use of a digital scale
accurate to 0.1 kg. The height was measured in a recumbent
position to the nearest 0.1 cm (length) for children aged ,2 y.
All weight and height values were reported to the French
growth charts established by Sempé and Pédron (15, 16).
Statistical analyses
Statistical analyses were performed with the use of R sta-
tistical software version 3.0.2, SPSS version 20.0 (SAS), and
Microsoft Office Excel 2010. Results of means were accom-
panied by 95% CIs. Student’s t and chi-square tests were used to
compare means and rates, respectively. Quantitative variables
were expressed as means 6 SDs. Factors associated to weaning
off HPN, ITx, and death were studied with the use of univariate
analyses. The a-risk threshold was set at P = 0.05.
RESULTS
HPN incidence and demographic data
Of the 251 children in the study, 137 (55%) were boys. The
incidence of new patients per year was 18 6 4 (range: 14–27).
The children in the first 7-y study period were referred mainly
from the IDF area. Later, the number of children coming from
outside IDF increased (Figure 1). The mean age at HPN onset
was 0.7 6 0.3 y (0.6 y for PDD and 1.3 y for PNDD).
Indications for HPN
The largest PDD subgroup included 148 children with SBS
(59%) (Table 1). The mean length of remnant small bowel was
50 6 14 cm (range: 2–90 cm), and the ICV was present in 76
patients (51%). Four children had SBS secondary to bowel
ischemia—3 after intussusception on Meckel diverticulum
and 1 panarteritis nodosa. Of the 25 children with congenital
enteropathies, 5 remained without a specific diagnosis (20%).
Rare causes of PDD (n = 8; 3%) included chylous ascitis (n = 3),
intestinal lymphangectasia with severe protein-losing enter-
opathy (n = 4), and Bannayan-Riley-Ruvalcaba syndrome (total
intestinal polyposis, n = 1). Thirty-four children had a PNDD
(14%) mostly because of ID (n = 25; 74%). Of these, 1 child
with an IL-10 receptor deficiency underwent bone marrow
transplantation and was weaned off PN. The age distribution at
HPN onset is shown in Table 2.
Outcome and prognosis factors
On 31 December 2013, 131 children (52%) of the entire cohort
were weaned off PN after 1.9 6 0.4 y. Eighty-seven children
(34%) were still receiving HPN, 12 of whom were referred to an
adult center. Table 3 shows factors influencing weaning off
HPN, ITx, and death. The patients who were most likely weaned
off HPN were those with IBD (P = 0.001) and SBS (P = 0.008).
Children with SBS who were weaned off HPN (n = 91) had
a bowel length of 76 6 6 cm, and 62% had intact ICV. Those
who were not weaned off HPN had a bowel length of 24 6 5 cm
(P = 0.001), and 35% had an ICV (P = 0.002). ITx was sig-
nificantly performed mostly in patients with SBS (P = 0.04) and
CE (P , 0.001). Death most likely occurred in patients with ID
(P , 0.001) or another PNDD (P = 0.002) and the least in SBS
patients (P , 0.001). IFALD was significantly associated with
less PN weaning (P = 0.043). CRBSIs did not influence the
outcome.
Complications
Hospitalizations and infections
The mean number of hospitalizations was 6.5/patient; 2.3
hospitalizations were related to CVC (35%). The mean number of
days in the hospital was 25 6 2/y. During the 14-y period, 318
episodes of CVC-related infections occurred: 287 episodes of
CRBSI (1.1 episode/patient) and 31 episodes of tunnelitis.
CRBSI was confirmed in 24% of cases of fever. During our
study period, the mean number of CRBSIs was 1.7 6 0.5/1000
d of PN. We had 2 peaks of CRBSI around 2.3/1000 d of HPN
TABLE 3
Factors influencing outcomes: univariate analyses1
n
HPN
duration, y
Weaning off ITx Death
n (%) P n (%) P n (%) P
SBS 148 1.9 6 0.42 91 (62) 0.008 10 (7) 0.04 2 (1) ,0.001
CE 25 2.2 6 0.3 0 (0) NA 8 (32) ,0.001 3 (12) 0.38
CIPOS 23 2.2 6 0.6 11 (48) 0.644 1 (4) 0.3 1 (4) 0.55
IBD 13 1.7 6 0.3 11 (85) 0.001 0 NA 0 0.18
Other PDDs 8 1.4 6 0.6 7 (90) NA 0 NA 0 NA
ID 25 1.2 6 0.4 9 (36) 0.088 0 NA 15 (60) ,0.001
Other PNDDs 9 3.3 6 0.6 2 (22) 0.06 0 NA 3 (33) 0.002
IFALD+ 51 20 (39) 0.043 7 (14) 0.44 2 (4) 0.3
.1 CRBSI 137 71 (52) 0.84 15 (11) 0.89 7 (5) 0.19
1Chi-square test was used for analyses. CE, congenital enteropathy; CIPOS, chronic intestinal pseudo-obstruction syndrome; CRBSI, catheter-related
bloodstream infection; IBD, inflammatory bowel disease; ID, immune deficiency; IFALD+, intestinal failure–associated liver disease in children with
abnormal liver function tests .1.5 times the upper limit of normal; ITx, intestinal transplantation; NA, not applicable; PDD, primary digestive disease;
PNDD, primary nondigestive disease; SBS, short bowel syndrome.
2Mean 6 SD (all such values).
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between 2007 and 2008 and in 2011 (Figure 2). Of those
children who had a CRBSI (n = 137), 34% had more than 1
episode of confirmed bacteremia (Table 4). Coagulase-negative
staphylococci were the most frequent pathogens involved in
CRBSI (Figure 3). At the end of our study, Taurolidine-citrate
locks (TauroLock) were used in 25 children with a mean follow-
up of 1.4 6 0.4 y. In those children, CRBSIs decreased from 5.2
to 0.2/1000 d of CVC (P = 0.001).
Catheter types, replacement, and thrombosis
Of the 251 children studied, nearly all (n = 249) had a Broviac-
type CVC; 2 had an arteriovenous fistula. A total of 133 cath-
eters had to be changed in 60 children (2.2/patient) after a mean
of 2.3 6 0.4 y. The indications for CVC replacement were
leakage or rupture (n = 60), Staphylococcus aureus (SA) or fungi
in CRBSIs (n = 45), CRBSI persistent for .48 h of targeted
antibiotherapy (n = 22), and CVC thrombosis with failure of
Actosolv (Urokinase) lock regimen (n = 6).
IFALD and liver biopsies
Of all 251 children, 68 (27%) had abnormal LFTs. In 17, they
were observed before starting HPN and were excluded from the
analysis. In the other 51 children (20%), the abnormalities were
seen after 2.9 6 2.3 y of HPN (median: 4.3 y). All children with
abnormal LFTs for .6 mo had a liver biopsy (transjugular,
n = 2; percutaneous, n = 49). Twenty-eight children had in-
creased transaminases (55%), 12 had increased bilirubin or
g-glutamyltranspeptidase (24%), and 11 had both (21%). On
follow-up, LFTs improved in 27 of 51 children (53%), were
stable in 16 (31%), and worsened in 8 (16%). Abnormal LFTs
were seen in 21% of children with PDD (n = 46) and 15% with
PNDD (n = 5). Children receiving PN for congenital enteropa-
thies had the highest prevalence of abnormal LFTs (44%)
(Table 5). Eighty-six liver biopsies were performed for the 51
children. The METAVIR score was F0 (no fibrosis) in 21 bi-
opsies (24%), F1 in 20 (24%), F2 in 21 (24%), F3 in 10 (12%),
and F4 (cirrhosis) in 14 (16%).
Intestinal transplantation
Nineteen children in the PDD subgroup (9%) underwent ITx (14
isolated ITx and 5 L-SBTx) after 2.86 0.8 y of HPN. Indications
were repeated life-threatening CRBSIs (n = 10), end-stage liver
disease (n = 5), extensive vascular thrombosis (n = 2), and re-
peated life-threatening dehydration episodes (n = 2). Within
18 mo after ITx, 95% (18 of 19) were weaned off HPN. One child
was weaned off HPN after 2.5 y. In 7 children (37%), the graft
TABLE 4
Incidence of CRBSI1
Total
CRBSIs, n
CRBSI/1000
d of PN
Children with
CRBSI, n
Children with .1
CRBSI, %
2000 23 2 15 28
2001 14 1.2 12 33
2002 20 1.8 16 33
2003 19 1.3 14 32
2004 18 1.1 11 25
2005 16 1.5 10 25
2006 19 1.8 12 30
2007 30 2.3 20 48
2008 29 2.3 19 42
2009 30 2 16 46
2010 17 1.6 12 36
2011 24 2.4 13 51
2012 16 1.5 11 32
2013 12 0.9 10 20
Mean 6 SD 20.5 6 5.9 1.7 6 0.5 13.6 6 3.2 34.4 6 9.3
1CRBSI, catheter-related bloodstream infection; PN, parenteral
nutrition.
FIGURE 2 Incidence of catheter-related bloodstream infection/1000
d of catheter use.
FIGURE 3 Percentage of microorganisms responsible for catheter-re-
lated bloodstream infections. CNS, coagulase-negative Staphylococcus; SA,
Staphylococcus aureus.
TABLE 5
Incidence of abnormalities in liver function tests1
Total children,
n
Children with abnormal
LFTs, n (%)
Mean time to
abnormal LFT, y
PDDs 217 46 (21) 3.0 6 1.6
SBS 148 28 (19) 3.2 6 1.8
CE 25 11 (44) 2.4 6 1.4
CIPOS 23 3 (13) 4.4 6 1.4
IBD 13 1 (8) 4.2
Other 8 3 (38) 1.6 6 0.8
PNDDs 34 5 (15) 2.1 6 1.4
ID 25 4 (16) 2.1 6 1.6
Other 9 1 (11) 2.3
1CE, congenital enteropathy; CIPOS, chronic pseudo-obstruction syn-
drome; IBD, inflammatory bowel disease; ID, immune deficiency; LFT, liver
function test; PDD, primary digestive disease; PNDD, primary nondigestive
disease; SBS, short bowel syndrome.
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was removed after a mean of 25 6 6 mo for rejection. Three
children died because of uncontrollable acute rejection after ITx.
Mortality
Twenty-four children died while receiving HPN (10%). They
were not included in the calculation of weaning rate and HPN
duration. Six children had a PDD (3% of the subgroup) and died
of ITx complications (n = 3), end-stage IFALD (n = 2), and
hypovolemic shock (n = 1). The other 18 children had a PNDD
(53% of the subgroup) and died of infections (ID; n = 15),
metabolic disease (n = 1), cardiomyopathy (n = 1), and re-
spiratory failure (n = 1). The longest duration of HPN in the
PNDD subgroup was 7 y. The death rate was significantly
higher in patients with PNDD (P , 0.001) (Figures 4 and 5).
Table 6 compares our results to the previous study performed
in our unit (6).
Growth in SBS and PN energy requirements
Ninety-one children with SBS were weaned off HPN at a mean
age of 2.96 0.6 y. There was no significant difference in weight-
for-age and height-for-age z scores at weaning off HPN and
follow-up visits (P = 0.23 and 0.16, respectively). For children
with SBS still receiving HPN at the end of the study period
(n = 45), the level of PN dependency assessed by the NPEI:REE
ratio was 1.31 6 0.2 (Table 7).
DISCUSSION
This study reports the long-term outcome of 251 children
enrolled in a single-center French HPN program over a 14-y
period. SBS is the leading indication for HPN (6, 18–22). In this
study, the delay to weaning off PN was 1.96 0.4 y, which is less
than we previously reported (6). This is probably because of
better surgical techniques developed in the past 10 y and early
oral feeding, which has promoted intestinal adaptation and led to
a better weaning rate and shorter duration of HPN (2, 3, 23, 24).
Children with SBS in our unit were not all early fed before 2000.
The current data confirm that children with SBS who were
weaned off HPN had a remaining bowel length .40 cm and
intact ICV (20, 24, 25).
In the PDD group, IBD had the highest rate of weaning off
HPN because of the use of biotherapies for the past 15 y. SBS is
a condition in which improvements and progressive autonomy
are achieved with good outcomes unless impaired by severe
complications. CIPOS is a chronic condition with a permanently
high level of PN dependency. Our CIPOS subgroup is biased with
the most severe forms included in this survey. Congenital en-
teropathies cause severe and permanent diarrhea. Their prognosis
is poor regarding the probability of PN weaning, and those
children are candidates for ITx. PNDD had the lowest weaning
rate mainly because of the poor prognosis of their underlying
disease.
The mortality rate was significantly lower than previously
reported by other studies (4, 6, 19, 26) because of better IF
management, including more adequate PN formulas, improved
CVC handling techniques, and clearer indications for ITx. The
major factors of morbidity were IFALD and CRBSI. The di-
agnosis of IFALD is difficult (9, 21, 27–31). Herein we recorded
LFTs. Children with CE showed the highest rate of IFALD.
As shown by Fitzgibbons et al. (30), LFTs were not always
FIGURE 4 Survival curves of children with primary digestive and nondigestive diseases. HPN, home parenteral nutrition.
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correlated to the degree of liver fibrosis. Different degrees of
fibrosis were found in 76% of biopsies in our patients
compared with 94% in the Peyret et al. study (21). These 2
cohorts are not comparable in terms of infection rates, types
of lipid emulsions used, and mode of enteral feeding. All
children received soybean oil, medium-chain triglycerides,
olive oil, and fish oil after 2008, but the follow-up is too
short for analysis or conclusion. However, increasing data
suggest its efficiency in preventing IFALD (5). Nontrans-
plant surgical procedures reduce the diameter of dilated
intestinal loops and may prevent IFALD by improving mo-
tility and reducing small intestine bacterial overgrowth (2, 3,
32). Our experience has been limited to 4 children (data not
shown).
We observed peaks of incidence of CRBSIs in 2007–2008
and 2011. The first peak correlated with changes in the CVC-
handling regimen in our unit. Increased rates of CRBSIs were
also reported in intensive care units when mechanical valve-
needleless connectors were introduced (33, 34). The CDC
stated that these valves do not increase the incidence of
CRBSIs when the access port is wiped with an appropriate
antiseptic (35, 36). In 2013, Hong et al. (37) showed a superior
activity of chlorhexidine-alcohol over povidone-iodine
(Betadine) (38). We suspect that the lack of appropriate dis-
infection explains the first peak of CRBSIs. We have no ex-
planation for the second peak. No statistical difference was
found between the PDD and PNDD subgroups.
Coagulase-negative staphylococci were the most frequent
cause of CRBSIs. As reported by Gandullia et al. (26), SA was
the major pathogen found in CRBSIs (42%). It was only 10% in
Moreau et al. (39). The overall incidence of SA increased in our
unit, leading to catheter replacement and longer antibiotic
treatment. Nevertheless, the incidence of CRBSIs decreased
after we began using Taurolidine-citrate locks in 2011. Hui-Ping
Chu et al. (40) showed a considerable decrease in CRBSIs from
8.6 to 1.1 episodes/1000 d of PN when using Taurolidine-citrate
by impeding bacterial adhesion and clot formation. Our results
FIGURE 5 Survival curve of the whole population. HPN, home parenteral nutrition.
TABLE 6
Our study results compared with those of Colomb et al. (6)1
Our study Colomb et al. P
Patients, n 251 302
Follow-up, y 14 20
Weaning rate, % 52 54 0.60
HPN duration to weaning, y 1.9 6 0.42 2.6 6 0.2 ,0.001
Days of hospitalization/y 25 6 2 39 6 7 ,0.001
CRBSI/1000 d of PN 1.7 6 0.5 1.2 6 0.2 ,0.001
Mean time to catheter
replacement, y
2.3 6 0.4 1.8 6 0.6 ,0.001
Prevalence of IFALD, % 20 23 0.40
Prevalence of IFALD in PDD, % 21 20 0.09
Prevalence of IFALD in PNDD, % 15 35 0.04
ITx in PDD subgroup, % 9 5.6 0.20
Mortality, % 10 16 0.03
1Student’s t test was used to compare means. The chi-square test was
used to compare rates. CRBSI, catheter-related bloodstream infection; HPN,
home parenteral nutrition; IFALD, intestinal failure-associated liver disease;
ITx: intestinal transplantation; PDD, primary digestive disease; PNDD, pri-
mary nondigestive disease.
2Mean 6 SD (all such values).
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are very promising, as suggested by the drop in CRBSI in-
cidence since 2012 (Figure 2).
In our experience, children respond well to Actosolv locks
(Urokinase) when CVC thrombosis is detected early. Only 6
children in our cohort had their CVC replaced for catheter
thrombosis because of Actosolv lock failure. The data on
thrombosis were not studied by Colomb et al. (6). Themechanical
valve needleless connectors we have used since 2007 claim to
reduce the incidence of thrombosis (34).
Data on the growth of children on long-term PN are scarce. In
2002, Colomb et al. (41) showed that normal growth was
achieved in only 25% of children receiving HPN. The failure to
thrive was because of a negative nitrogen balance and insufficient
energy. Recent data from Pichler et al. (42, 43) showed better
growth in children receiving HPN (SD of 20.8 6 1.3 for weight
and21.86 1.5 for height). Children with SBS have a major risk
of decreased growth velocity after weaning off of HPN (25, 44).
In this cohort, growth remained normal 6 mo after weaning off
of HPN. A longer follow-up is needed to identify the children
that will require nutritional support, especially during the onset
of puberty (25, 44, 45). Our experience showed that NPEI from
PN 1.5 times the REE allows normal growth in children who
were not malnourished (data not shown). Herein the ratio for
SBS children was 1.31 6 0.2. During follow-up, this ratio is
routinely calculated, and its decrease is an additional criterion
that the child is on the path of HPN weaning.
Several articles from the United States deal with “intestinal
rehabilitation centers,” including early management of IF,
especially SBS in both neonatology and surgical wards, with
the aim of the earliest PN weaning (46–53). Some patients
develop severe complications and become candidates for ITx,
whereas others fail to be weaned off of PN and are discharged
while receiving HPN when suitable. Unfortunately, to our
knowledge there is almost no specific report in the literature
about the prevalence and results of pediatric HPN programs
that makes any comparison with North America possible. One
of the reasons is probably related to the differences in the
organization and management of IF. The latter are supposed
to be shared between pediatric gastroenterology and nutrition
teams and home caregiver companies according to the local
facilities. In France, patients suffering from IF, including
those with SBS, are managed by specialized medical-surgical
departments, including pediatric surgeons and pediatric gas-
troenterologists, nutritionists, and neonatologists. The deci-
sion of discharging the child receiving HPN and the follow-up
are fully dependent on pediatric gastroenterology and nutri-
tion teams. The French network is organized regionally. Pa-
tients are referred to the closest of the 7 reference centers for
HPN. Our experience makes us the reference center for
a large part of the region. In 2014, of the 262 children who
received HPN, 108 (41%) were included in our HPN program.
These results reflect our specific management according to the
guidelines of the European Society of Pediatric Gastroenter-
ology, Hepatology and Nutrition 2005 and validated protocols.
As reported from a European expert panel, an important differ-
ence in clinical practice with North America is our limited use of
tube feeding (23). HPN for SBS is mostly based on the combi-
nation of cyclical nocturnal PN infusion and oral feeding during
the day.
Interestingly, in 1987, our institution became the first European
center for pediatric ITx. According to the Intestinal Transplant
Registry, only half of thew1700 transplanted pediatric patients
are now alive. We do consider that only patients with “nutri-
tional failure” had an increased risk of death while receiving
HPN, thus suggesting ITx should be only a life-saving proce-
dure (1, 12, 54). The latest data reported at the International
Small Bowel Transplantation Symposium (Buenos Aires, June
2015) confirmed this result as well as the worldwide reduc-
tion in ITx in children because of better IF care, including
nontransplant surgery and the use of fish oil-based lipid emul-
sions (5, 55).
SBS was the major indication for HPN in our cohort. In our
opinion and according to the prognosis after ITx, long-term
HPN remains the first-line management for children suffering
from IF and confirms continuous improvement, as suggested by
shorter HPN duration and decreased mortality. HPN allows
normal growth, but close and long-term clinical and biological
follow-up after weaning off HPN is mandatory. The probability
of weaning is mostly influenced by the underlying disease.
CRBSIs decreased after the introduction of TauroLock. IFALD
prevalence is low compared with reports in the literature. Fi-
nally, early referral to an IF expert center is mandatory for
decreasing the rate of complications and discussing ITx in
selected cases.
The authors’ responsibilities were as follows—EAN and OG: designed
the research and analyzed the data; EAN, CL, FL, and OG: wrote the
manuscript; EAN: had primary responsibility for the final content; and all
authors: conducted the research, oversaw the clinical management, and read
and approved the final manuscript. None of the authors reported a conflict of
interest related to the study.
TABLE 7
Growth of children with SBS while receiving HPN and 6 mo after weaning1
HPN duration, y
Weight-for-age
z score
Height-for-age
z score BMI, kg/m2 NPEI:REE2
At HPN weaning (n = 91) 1.4 6 1.0 20.49 6 1.1 20.2 6 1.4 15.9 6 1.6 0
6 mo after weaning off of HPN 20.71 6 0.93 20.1 6 2.14 15.4 6 2.2 0
Still receiving HPN (n = 45) 4.7 6 3.8 20.48 6 1.1 20.50 6 1.3 16.2 6 2.3 1.31 6 0.2
1Values are means 6 SDs. The chi-square test was used to compare means. HPN, home parenteral nutrition; NPEI,
nonprotein energy intake; REE, resting energy expenditure; SBS, short bowel syndrome.
2REE estimated with the use of Schofield equations.
3P = 0.23.
4P = 0.16.
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